Elevation Oncology Inc. has picked up the global rights to SYSA-1801, an anti-Claudin 18.2 antibody-drug conjugate (ADC) candidate, from CSPC Megalith Biopharmaceutical Co. Ltd. in a deal worth up to $1.195 billion. Under the terms, Elevation gets rights to develop and commercialize SYSA-1801 outside of mainland China, Hong Kong, Macau and Taiwan. Read More
After bottoming out at the end of May, BioWorld’s Drug Developers Index is making a slow, tedious climb back upwards. The index was down 23.18% for the year as of July 27, which is better than where it was at the end of each of the three prior months. It is following the same curve as the Nasdaq Biotechnology Index and the Dow Jones Industrial Average, which are down by 16.47% and 11.39%, respectively. Read More
The $65 million series A money banked by Vicinitas Therapeutics Inc. will boost efforts with the company’s Deubiquitinase Targeting Chimera (DUBTAC) platform, developed by way of an academic-industry research collaboration between the Novartis Institutes for Biomedical Research and researchers at the University of California, Berkeley. Read More
Keeping innovation growing at a fast clip while retaining new global supply chain capacity built up during the pandemic were the main topics of discussion at the Bio Asia-Taiwan conference July 27 in Taipei. With the theme of the conference, “Connecting the Asia Value Chain,” Taiwan Vice President Ching-Te Lai said the pandemic has demonstrated Taiwan’s resilience as well as the strength of the global biopharma industry. Read More
After an eight-year odyssey, the first cytidine triphosphate synthase 1 (CTPS1) inhibitor has entered the clinic, with Step Pharma SAS announcing it has simultaneously begun studies in the U.S. and the U.K. The phase I/II trial is assessing Step’s lead program, STP-938, in relapsed/refractory B- and T-cell lymphomas, with the first U.S. site opening for enrollment this week. Read More
While the U.S. Senate Finance Committee is ostensibly investigating how big pharma is using the 2017 tax changes to avoid paying its fair share of U.S. taxes, at least one medical device company has been drawn into the probe and is being scolded for not cooperating. Read More
Aging is surprisingly dichotomous. Genetic studies suggest that in fruit flies and mice, the gene sets that affect male and female longevity are mostly distinct. And a lopsided amount of what’s known about aging comes from the study of – wait for it – males. Read part three of BioWorld’s multipart series on extending the human lifespan. Read More
In Extending the human lifespan, a BioWorld special report, the team examined the latest science, the key biological drivers that can be targeted pharmacologically and the companies developing potential “Fountain of Youth” candidate drugs. In this episode of the BioWorld Insider Podcast, the team discussed the report’s highlights and key takeaways.
Please take a few minutes to fill out this short survey to help us provide you with the best possible source of news. Customer feedback is critical so that we can make BioWorld a valuable component of your daily workflow. We want to continue to evolve to serve you. The survey should take just 5 minutes. You can click through to the questions here. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 180, Abcellera, Aim, Akari, Alnylam, Altamira, Angion, Artizan, Assembly, Aurinia, Microviable, Pharmacyte, Spexis Sun, X4, Zyversa. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Lexicon, MBX, Novartis, Soligenix, Veru. Read More
